GlassScriptPhysician profile
Ann Petrillo
NPI 1396985057
$1,430.00
in general payments reported to CMS, 2019-2025
14 companies · $848 in 2025
The $848 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $101 · 2024: $481 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.87 | 2023-2025 | Jardiance |
| Pfizer INC. | $314.74 | 2024-2025 | |
| Novo Nordisk INC | $192.71 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $141.42 | 2024-2025 | Verquvo |
| Esperion Therapeutics, INC. | $89.52 | 2024-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $72.50 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $69.06 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $65.11 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $32.45 | 2024-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $29.24 | 2025 | Camzyos |
| Glaxosmithkline, LLC. | $24.42 | 2025 | Arexvy, Shingrix |
| Edwards Lifesciences Corporation | $21.19 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $16.58 | 2025 | Repatha |
| Lilly USA, LLC | $14.19 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Petrillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.